Company Filing History:
Years Active: 2021
Title: Lorena Saelices Gomez: Innovator in Transthyretin Aggregation Inhibition
Introduction
Lorena Saelices Gomez is a prominent inventor based in Los Angeles, California. She has made significant contributions to the field of biochemistry, particularly in the area of transthyretin (TTR) aggregation. Her innovative work focuses on developing peptide inhibitors that can effectively combat TTR-related diseases.
Latest Patents
Lorena holds a patent titled "Inhibition of the aggregation of transthyretin by specific binding of peptides to aggregation-driving segments." This invention relates to peptide inhibitors designed to prevent the aggregation of TTR, which is crucial in addressing cytotoxicity and TTR amyloidosis. The patent outlines a composition that includes at least one peptide aimed at inhibiting TTR aggregation, often coupled with a heterologous amino acid tag. Additionally, it describes a method for blocking TTR aggregation by combining TTR with an effective amount of the inhibitory peptide or pharmaceutical composition.
Career Highlights
Lorena is affiliated with the University of California, where she continues her research and development in the field of biochemistry. Her work has garnered attention for its potential impact on treating diseases associated with TTR aggregation.
Collaborations
Lorena collaborates with David S Eisenberg, a fellow researcher, to further explore the implications of her inventions in the scientific community.
Conclusion
Lorena Saelices Gomez is a trailblazer in the field of transthyretin aggregation inhibition, with her innovative patent contributing to advancements in medical science. Her work exemplifies the importance of research in developing effective treatments for complex diseases.